Black Diamond Therapeutics ( BDTX ) is a clinical stage biotechnology firm. Their main candidate, BDTX-1535 or Silvertinib, is currently investigated in first line and advanced lines in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). Silvertinib is entering anAt ELAM1, we empower financial professionals and investors with the scientific and clinical expertise required to navigate the complexities of the healthcare sector. By bridging the gap between cutting-edge science and financial strat ...